What Does del(5q) MDS Mean for Prognosis and Lenalidomide?

In myelodysplastic syndrome (MDS), a del(5q) result means a portion of chromosome 5 is missing in your abnormal bone marrow cells. This is a chromosomal deletion (a cytogenetic abnormality), not a gene mutation.

Finding a del(5q) deletion is important because it identifies a specific subtype of MDS that often progresses more slowly and can respond very well to a targeted treatment called lenalidomide ^[1][2]. However, the deletion alone does not tell the whole story. Your overall prognosis depends on a combination of factors: whether the del(5q) is “isolated,” your bone marrow blast percentage, your blood counts, your need for transfusions, and your overall IPSS-R or IPSS-M risk score ^[3].

Why “Isolated” del(5q) Matters

When your doctor looks at your cytogenetics (the chromosomal makeup of your MDS cells), they are checking to see if the del(5q) deletion stands alone or is part of a broader pattern of genetic damage.

• Isolated del(5q): According to current diagnostic classifications, this means you have the del(5q) deletion either entirely alone, or with exactly one other chromosomal abnormality ^[1]. (Note: If that one additional abnormality is the loss of chromosome 7 or del(7q), it excludes you from the lower-risk isolated category ^[1]). Patients with true isolated del(5q) and low bone marrow blasts generally fall into a lower-risk MDS category, which is associated with longer survival and a lower chance of rapid transformation to acute myeloid leukemia (AML) ^[1][4].
• Complex Karyotype: If you have three or more total chromosomal abnormalities (including the del(5q)), your disease is considered to have a “complex karyotype” ^[4]. This generally points to higher-risk disease, where survival outcomes tend to be shorter and the disease is less likely to respond to standard del(5q) therapies ^[5][4].

Anemia and Transfusion Patterns

MDS with isolated del(5q) has a distinct profile in your blood. It is typically characterized by macrocytic anemia (where the red blood cells are larger than usual) and often a normal or elevated platelet count ^[6].

The symptoms of your anemia (like fatigue and shortness of breath) happen because your bone marrow is not producing enough normal red blood cells or hemoglobin to carry oxygen effectively. Disease progression varies widely from person to person. You may not need transfusions immediately, but some patients eventually become transfusion-dependent ^[7]. The need for frequent red blood cell transfusions is an important clinical milestone; it is associated with a shorter overall survival time and requires careful monitoring for iron overload, a complication of repeated transfusions that may require separate management ^[7][8].

Lenalidomide: Treatment for Symptomatic Anemia

Having a del(5q) deletion does not automatically mean you need medication immediately. If your anemia is mild, your doctor may recommend observation. However, if your anemia is symptomatic or you rely on transfusions, an oral medication called lenalidomide is often the primary treatment ^[2]. It can preferentially suppress the abnormal del(5q) clone and help restore normal red blood cell production.

• Response Rates: In clinical studies, roughly 56% to 67% of lower-risk del(5q) patients treated with lenalidomide achieved complete red blood cell transfusion independence ^[2][9].
• Timeline to Response: It usually takes about 3 to 4 months of treatment to evaluate the full benefit, though responses can occur earlier ^[9][10].
• Long-Term Use: If the drug works for you, it is typically continued as long as it is effective and side effects are manageable ^[11]. If you eventually stop the drug while transfusion-independent, the benefit can sometimes last for months or years, and retreatment may be an option if you relapse ^[11][12].

Safety, Side Effects, and Monitoring

Lenalidomide is a powerful drug that suppresses both abnormal and healthy bone marrow cells, and it comes with strict safety warnings:

• Pregnancy and Blood Clots: Lenalidomide can cause severe birth defects, so it is strictly regulated under a risk-management program requiring pregnancy testing and contraception. It also carries a risk of blood clots, so your doctor may evaluate you for preventive blood thinners.
• Cytopenias: The drug commonly causes neutropenia (low white blood cells, increasing infection risk) and thrombocytopenia (low platelets, increasing bleeding risk) ^[13]. In clinical trials, roughly half of patients experienced severe neutropenia ^[13].
• Monitoring Schedule: You will likely need frequent complete blood counts (CBCs)—often weekly during the first two months—to monitor for drops in your blood counts. Dose reductions and temporary treatment holds are very common and normal parts of managing this therapy.
• When to Call: Contact your care team immediately if you develop a fever, signs of infection, unusual bleeding, black stools, severe rash, or sudden shortness of breath.

Even in lower-risk isolated del(5q) MDS, the disease can evolve. While your risk of progressing to AML is lower than in many other MDS types, it is not zero (for context, one observational study of treated patients saw an AML progression rate of roughly 12.7% at two years) ^[14]. Your doctor will monitor your blood counts regularly and may perform repeat bone marrow biopsies if your counts worsen, your blasts rise, or treatment decisions need to be adjusted ^[14][12].

The Impact of TP53 Mutations

Separate from your chromosomal deletions, doctors will also check your MDS cells for specific gene mutations. The TP53 gene normally helps prevent cancer, and mutations here can significantly alter your risk profile ^[3].

• Multi-Hit vs. Monoallelic: Risk depends on the “allelic state.” If both copies of the TP53 gene are disabled (either by two mutations, or one mutation plus the loss of the other copy), this is called “multi-hit.” Multi-hit TP53 increases the risk of the disease resisting treatment and transforming into AML ^[3][15]. If only one copy is mutated (monoallelic), the risk is generally lower.
• Variant Allele Frequency (VAF): This measures the percentage of DNA sequencing reads that carry the mutation, giving a rough estimate of the mutation’s size in your marrow. Studies have shown that a low VAF (under 20%) often behaves similarly to having no mutation at all, whereas a higher VAF is associated with higher risk ^[3].
• The del(5q) Context: Interestingly, research suggests that if you have multi-hit TP53 but an isolated del(5q) deletion, your prognosis may still be longer than someone with multi-hit TP53 who does not have the del(5q) deletion ^[15].

Always discuss your specific TP53 results with your hematologist, as this information is used alongside your blast count and blood counts to create a personalized care plan.